Log In
Register Now

Glenmark Pharmaceuticals secures US FDA approval for Olopatadine ophthalmic solution

Share it

Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,480.05, down by ₹6.50, or 0.44%, on the BSE.

Author picture

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Article

Open an Account in less than 1 Min.

Register Now
Need help? Call us

+919594214078

Services

Company

Get in touch

  • +919594214078
  • info@markettrade.live
  • Pjazza Mifsud Bonnici, Marsascala, Malta
  • 333, Pali Pathar, Khar West, Mumbai, Maharashtra 400052
Facebook-f Instagram Telegram Youtube
Copyright © 2025 Marketrade Private Limited